Cite
Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.
MLA
Baker, Jason V., et al. “Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.” Open Forum Infectious Diseases, vol. 4, no. 4, Fall 2017, p. N.PAG. EBSCOhost, https://doi.org/10.1093/ofid/ofx262.
APA
Baker, J. V., Sharma, S., Grund, B., Rupert, A., Metcalf, J. A., Schechter, M., Munderi, P., Aho, I., Emery, S., & Babiker, A. (2017). Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. Open Forum Infectious Diseases, 4(4), N.PAG. https://doi.org/10.1093/ofid/ofx262
Chicago
Baker, Jason V, Shweta Sharma, Birgit Grund, Adam Rupert, Julia A Metcalf, Mauro Schechter, Paula Munderi, Inka Aho, Sean Emery, and Abdel Babiker. 2017. “Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.” Open Forum Infectious Diseases 4 (4): N.PAG. doi:10.1093/ofid/ofx262.